- Home
- SBLK vs COGT Comparison
SBLK vs COGT Comparison
Compare SBLK & COGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SBLK
- COGT
- Stock Information
- Founded
- SBLK 2006
- COGT 2014
- Country
- SBLK Greece
- COGT United States
- Employees
- SBLK N/A
- COGT N/A
- Industry
- SBLK Marine Transportation
- COGT Biotechnology: Pharmaceutical Preparations
- Sector
- SBLK Consumer Discretionary
- COGT Health Care
- Exchange
- SBLK Nasdaq
- COGT Nasdaq
- Market Cap
- SBLK 2.1B
- COGT 2.3B
- IPO Year
- SBLK N/A
- COGT 2018
- Fundamental
- Price
- SBLK $19.06
- COGT $36.63
- Analyst Decision
- SBLK Strong Buy
- COGT Buy
- Analyst Count
- SBLK 1
- COGT 13
- Target Price
- SBLK $22.00
- COGT $28.08
- AVG Volume (30 Days)
- SBLK 889.6K
- COGT 4.8M
- Earning Date
- SBLK 11-18-2025
- COGT 11-03-2025
- Dividend Yield
- SBLK 1.06%
- COGT N/A
- EPS Growth
- SBLK N/A
- COGT N/A
- EPS
- SBLK 0.53
- COGT N/A
- Revenue
- SBLK $1,050,829,000.00
- COGT N/A
- Revenue This Year
- SBLK N/A
- COGT N/A
- Revenue Next Year
- SBLK $19.06
- COGT N/A
- P/E Ratio
- SBLK $36.45
- COGT N/A
- Revenue Growth
- SBLK N/A
- COGT N/A
- 52 Week Low
- SBLK $12.06
- COGT $3.72
- 52 Week High
- SBLK $19.99
- COGT $37.08
- Technical
- Relative Strength Index (RSI)
- SBLK 56.56
- COGT 83.97
- Support Level
- SBLK $18.74
- COGT $32.85
- Resistance Level
- SBLK $19.61
- COGT $36.29
- Average True Range (ATR)
- SBLK 0.49
- COGT 2.62
- MACD
- SBLK 0.06
- COGT 1.10
- Stochastic Oscillator
- SBLK 69.81
- COGT 98.45
About SBLK Star Bulk Carriers Corp.
Star Bulk Carriers Corp provides seaborne transportation solutions in the dry bulk sector. The company owns and operates dry bulk carrier vessels, which are used to transport bulk, such as iron ore, coal, grains, bauxite, fertilizers, and steel products. It owns a fleet of vessels that consists of Newcastlemax, Capesize, Post Panamax, Kamsarmax, Panamax, Ultramax, and Supramax. It generates revenues through the voyages it carries out.
About COGT Cogent Biosciences Inc.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.